AstraZeneca PLC (AZN)vsSol Gel Technologies Ltd (SLGL)
AZN
AstraZeneca PLC
$160.17
+0.33%
HEALTHCARE · Cap: $252.33B
SLGL
Sol Gel Technologies Ltd
$65.94
-1.27%
HEALTHCARE · Cap: $227.61M
Smart Verdict
WallStSmart Research — data-driven comparison
AstraZeneca PLC generates 3418619% more annual revenue ($61.37B vs $1.79M). AZN leads profitability with a 17.0% profit margin vs 0.0%. AZN earns a higher WallStSmart Score of 60/100 (C+).
AZN
Buy60
out of 100
Grade: C+
SLGL
Avoid26
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+18.4%
Fair Value
$196.10
Current Price
$160.17
$35.93 discount
Intrinsic value data unavailable for SLGL.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 21 in profit
Strong operational efficiency at 23.5%
Generating 2.1B in free cash flow
Earnings expanding 487.6% YoY
Conservative balance sheet, low leverage
Areas to Watch
2.5% earnings growth
Distress zone — elevated risk
Smaller company, higher risk/reward
0.0% margin — thin
Weak financial health signals
ROE of -2.0% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : AZN
The strongest argument for AZN centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 17.0% and operating margin at 23.5%. PEG of 1.28 suggests the stock is reasonably priced for its growth.
Bull Case : SLGL
The strongest argument for SLGL centers on EPS Growth, Debt/Equity.
Bear Case : AZN
The primary concerns for AZN are EPS Growth, Altman Z-Score.
Bear Case : SLGL
The primary concerns for SLGL are Market Cap, Profit Margin, Piotroski F-Score.
Key Dynamics to Monitor
AZN profiles as a mature stock while SLGL is a value play — different risk/reward profiles.
SLGL carries more volatility with a beta of 1.13 — expect wider price swings.
AZN is growing revenue faster at 6.4% — sustainability is the question.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
AZN scores higher overall (60/100 vs 26/100), backed by strong 17.0% margins. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
Sol Gel Technologies Ltd
HEALTHCARE · BIOTECHNOLOGY · USA
Sol-Gel Technologies Ltd., a specialty clinical-stage pharmaceutical company, is focused on developing and commercializing topical dermatological pharmaceuticals based on its Israel-patented microencapsulation delivery system. The company is headquartered in Ness Ziona, Israel.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?